Biopharma Vical (NASDAQ:VICL) has risen to its highest share price in a year — and with rumors of a buyout offer, it shows no sign of stopping.

The share price for Vical Incorporated (NASDAQ:VICL) jumped over 15% earlier this month on the news that a U.S. patent had been granted for its Vaxfectin-formulated DNA influenza vaccines.

Now with the addition of rumors of a buyout offer from generic drug giant Teva Pharmaceuticals Ltd. (NASDAQ:TEVA), this company is rapidly becoming a superstar!

We saw the potential for Vical here at TFN. Readers that acted on our FREE recommendation of VICL in our Aug. 20 Report, The Top 6 Swine Flu Vaccine Stocks Under $20 are sitting on gains of around 46%!

The rumors could prove true

In early August, Vical announced an agreement with a subsidiary of Teva (Abic Marketing Limited) allowing Abic exclusive marketing rights for the company’s drug Allovectin-7 in Israel.

In return, Vical is to receive upfront and milestone payments.

The company is currently enrolling patients for the Phase III trial of Allovectin-7 in Israel for the treatment of metastatic melanoma.

Teva may perceive Vical as a worthwhile purchase. If you own shares of Vical, we recommend you hold on for now.

Source: Vical (VICL) Just Keeps on Giving